GROVES REGINA E 4

What Happened
Regina Groves, a director of Fulgent Genetics, was granted 11,117 restricted stock units (RSUs) on May 14, 2026. The grant price reported is $0.00, so there was no cash exchanged at grant; the reported dollar value at grant is $0. This is an award/compensation grant (transaction code A), not an open‑market purchase or sale.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (timely filing).
• Award: 11,117 RSUs; grant price reported as $0.00; aggregate dollar amount reported $0.
• Shares owned after transaction: not specified in the supplied filing details.
• Footnote: RSUs vest over four years — 1/4 of the shares vest 12 months after May 14, 2026 (around May 14, 2027), then 1/16 of the total shares vest at the end of each three‑month period thereafter over the next 36 months, subject to continued service.
• Transaction type: Award/Grant (RSUs), code A.

Context
RSU grants are a form of compensation for directors and typically vest over time contingent on continued service; they do not represent an immediate cash investment or sale. Because this is a compensation award rather than an open‑market purchase, it should be interpreted as part of director pay rather than a direct private signal of the director’s near‑term market view.